Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

Background In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. Methods Adults with various solid tumours refractory t...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of cancer Vol. 122; no. 11; pp. 1630 - 1637
Main Authors:	Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 26.05.2020 Nature Publishing Group
Subjects:	692/4028/67/1059/153 692/4028/67/1059/602 Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Biomedical and Life Sciences Biomedicine Cancer Research Cancer therapies Dexamethasone Drug Resistance Dyspnea Epidemiology Female Fever Gene expression Hepatocellular carcinoma Humans Leukocytes Liposomes - adverse effects Liposomes - pharmacokinetics Liver cancer Male Maximum Tolerated Dose MicroRNAs MicroRNAs - administration & dosage MicroRNAs - adverse effects MicroRNAs - pharmacokinetics Middle Aged miRNA Molecular Medicine Nanoparticles - administration & dosage Nanoparticles - adverse effects Nausea Neoplasms - drug therapy Oncology Patients Pharmacodynamics Respiration Solid tumors Toxicity Tumors
ISSN:	0007-0920, 1532-1827, 1532-1827
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!